Revenue Sources.. Again this is old news but this is where Protokinetixs will start bring in needed revenue... Mr. Senior(CEO), Had stated that alot of research though other companies had finished and PR News would be out soon...Good reading.
Revenue Sources
According to Euromonitor research, global sales of anti-aging products have increased by 108.5% since 1997, and as of 2006 are now worth 9.8 billion US dollars a year.
Protokinetix Inc. has completed the required research work to demonstrate the effectiveness of AAGP™ as an anti-aging molecule. Repeated experiments have confirmed that AAGP™ has the following characteristics which are valued in the cosmetic industry:
epithelial fibroblasts and keratinocytes live significantly longer
cells are healthier
cells function normally
cells are protected from harsh environmental pollutants a. Ultraviolet radiation (A,B, and C) b. Strong oxidizing agents (tested on hydrogen peroxide)
damaged cells are repaired
there is no toxicity
stable compound
soluble in water and in oils
The competition in this field includes anti-oxidants such as Coenzyme Q 10, Vitamin creams (Retinol which has Vitamin A, as well as vitamin C creams), and synthetic tetrapeptides.
These agents each have a demonstrated role in anti-aging.
Coenzyme Q10 is a free radical trap and in it is able to keep cells alive longer, but as the graph earlier in this paper shows, it is inferior to AAGP™.
Vitamin A creams as well as vitamin C creams function as free radical blocks.
The tetrapeptides play a role in collagen synthesis.
There is no other product that has the same features as are seen in AAGP™.
Protokinetix Inc. has been in discussions with a number of cosmetic and skin care companies.
Two of these companies are at this time testing AAGP™ in their formulations to confirm that they are able to reproduce the work we have done.
We have a meeting scheduled with the world’s largest cosmetic company for the 23rd of May, 2007. Three senior executives will fly from France to meet with us in Vancouver.
Protokinetix has made initial contact with experienced individuals who have a proven tract record in contract negotiations. Once we have completed the scale up production of the molecule we will form a business development group and to negotiate contracts with major companies in the cosmetic and skin care industries.
The goal will be to have some up front funding and a royalty stream. The second revenue stream will come from the sale of AAGP™ to research facilities, universities and companies that provide cells for research and storage of specialized cells.
The North American market for supplying cell lines for research exceeds 700 million dollars per year. The largest company in this market has confirmed their interest in AAGP™. This company is presently working with AAGP™ to confirm our results.
In addition to this one large company, Protokinetix has been contacted by many different institutions that want the product. Once scale up is completed, this market will be developed as a source of ongoing revenue by the business development group. It is anticipated that this market will be available to Protokinetix in the 2007 fiscal year.
AI
